BridgeMD
New treatment option for Insulin Resistance
Official title Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity
ClinicalTrials.gov ID: NCT07327684
What this study is testing
- What it's testing
- The goal of this study is to develop a novel, non-invasive, real-time photoacoustic imaging (PAI) technology for quantifying brown adipose tissue (BAT) and to investigate the differences in BAT morphology and metabolic function between healthy individuals and patients with metabolic syndrome. The main questions it aims to answer are: 1.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80. Healthy volunteers may be eligible.
You may be able to join if
- Criteria for Healthy people: ()
- Healthy individuals over 18 years of age.
- Body Mass Index (BMI) \< 30.
- No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases.
- Not currently using any sympathomimetic or sympatholytic drugs.
You likely can't join if
- Weight change \> 5% within 3 months prior to enrollment.
- BMI ≥ 30.
- Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular and cerebrovascular disease, or malignant tumor.
- Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment.
- Smoker or consumes excessive alcohol.
- Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation.
See the full eligibility criteria
- Criteria for Healthy people: ()
- Healthy individuals over 18 years of age.
- Body Mass Index (BMI) \< 30.
- No history of metabolic diseases, rheumatic immune diseases, or cardiovascular and cerebrovascular diseases.
- Not currently using any sympathomimetic or sympatholytic drugs.
- Non-smoker and does not consume excessive alcohol. (
- Weight change \> 5% within 3 months prior to enrollment.
- BMI ≥ 30.
- Diagnosis of metabolic disease, rheumatic immune disease, cardiovascular and cerebrovascular disease, or malignant tumor.
- Use of sympathomimetic or sympatholytic drugs within 3 months prior to enrollment.
- Smoker or consumes excessive alcohol.
- Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation.
- Currently pregnant, lactating, or menstruating.
- Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination. Criteria for Patients with Metabolic Syndrome and Insulin...
- Age between 18 and 60 years.
- Must meet 3 or more of the following criteria:
- Waist circumference ≥ 90 cm for males, ≥ 85 cm for females.
- Fasting blood glucose ≥ 6.10 mmol/L (110 mg/dl) OR 2-hour postprandial blood glucose ≥ 7.80 mmol/L (140 mg/dl) OR previously diagnosed diabetes.
- Blood pressure ≥ 130/85 mmHg OR previously diagnosed hypertension and under treatment.
- Fasting triglycerides (TG) ≥ 1.7 mmol/L (150 mg/dl).
- Fasting high-density lipoprotein cholesterol (HDL-C) \< 1.0 mmol/L (40 mg/dl).
- Patients diagnosed with Polycystic Ovary Syndrome (PCOS), defined as meeting two or more of the following criteria and excluding other endocrine diseases that could cause similar symptoms: hyperandrogenism, ovulatory...
- Diagnosis of Type 1 diabetes or other specific types of diabetes.
- Presence of acute diabetic complications or severe chronic diabetic complications.
- History of acute or chronic pancreatitis, or pancreatic tumors.
- Heart failure, unstable angina, myocardial infarction within the past 12 months, cerebral infarction, severe arrhythmia, or severe hypertension (blood pressure \> 180/110 mmHg despite antihypertensive medication).
- Severe hepatic or renal dysfunction.
- Comorbid malignant tumors or other severe chronic diseases.
- Received glucose-lowering therapy within 3 months prior to enrollment OR a total of more than 3 months of glucose-lowering therapy in the past 2 years.
- Diagnosis of rheumatic immune diseases.
- Diagnosis of Raynaud's disease, or intolerance/allergy to cold stimulation.
- Currently pregnant, lactating, or menstruating.
- Contraindications to the injection of the radionuclide tracer Fluorodeoxyglucose (18F-FDG) or other conditions unsuitable for PET-CT examination.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.